Current Report Filing (8-k)
January 07 2020 - 4:49PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 1, 2020
EIDOS THERAPEUTICS, INC.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
Delaware
|
|
001-38533
|
|
46-3733671
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
Eidos Therapeutics, Inc.
101 Montgomery Street, Suite 2000
San Francisco, CA 94104
(Address of principal executive offices, including zip code)
(415) 887-1471
(Telephone number, including area code, of agent for service)
Not Applicable
(Former
name or former address, if changed since last report.)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock
|
|
EIDX
|
|
The Nasdaq Global Select Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☒
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
Appointment of Franco Valle as Principal Accounting Officer
On January 1, 2020, Eidos Therapeutics, Inc. (the Company) appointed Franco Valle as the Companys Senior Vice President, Finance and
principal accounting officer, effective immediately. Mr. Valle succeeds Christine Siu as the Companys principal accounting officer.
Mr. Valle, 39, joined the Company as its Vice President, Finance in March, 2018. Before he joined the Company from July 2016 to January 2018 he worked at
Iovance Biotherapeutics, Inc. as the Controller and principal accounting officer. Prior thereto, from May 2012 through April 2016 Mr. Valle worked at Pharmacyclics, Inc. in various positions, including most recently as the senior director of
accounting. Prior thereto, Mr. Valle was the SEC reporting manager of Callidus Software, Inc. from October 2011 to May 2012. From July 2005 to October 2011, Mr. Valle worked at PricewaterhouseCoopers LLP in the life science, biotech and
venture capital group. Mr. Valle is a certified public accountant and a graduate of San Jose State University.
There are no arrangements or
understandings between Mr. Valle and any other persons pursuant to which he was appointed as principal accounting officer of the Company, and Mrs. Valle has no family relationship with any director or executive officer of the Company.
Mr. Valle is not a party to any current or proposed transaction with the Company for which disclosure would be required under Item 404(a) of Regulation S-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Eidos Therapeutics, Inc.
|
|
|
|
|
Date: January 7, 2020
|
|
|
|
By:
|
|
/s/ Neil Kumar
|
|
|
|
|
|
|
Neil Kumar
|
|
|
|
|
|
|
Chief Executive Officer
|
Eidos Therapeutics (NASDAQ:EIDX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Eidos Therapeutics (NASDAQ:EIDX)
Historical Stock Chart
From Sep 2023 to Sep 2024